Importance of Copy Number Variant Analysis in Patients with Monogenic Kidney Diseases: Insights from 8 Years of Experience in an Expert Centre's Genome Diagnostic Laboratory

Background: Genetic testing can reveal monogenic causes of kidney diseases, offering diagnostic, therapeutic, and prognostic benefits. While single nucleotide variants (SNVs) and copy number variants (CNVs) can result in kidney disease, CNV analysis is not always included in genetic testing. With read depth-based tools for CNV detection (e.g. ExomeDepth) emerging, massively parallel sequencing can detect both SNVs and CNVs. This makes CNV detection more efficient as it does not require a separate test (e.g. SNP-array, MLPA). Methods: We investigated the diagnostic value of CNV analysis in 2,432 kidney disease patients genetically tested at the University Medical Centre Utrecht between 2014 and May 2022. We combined previous diagnostic testing results, encompassing SNVs and CNVs, with newly acquired results based on retrospective CNV analysis. The reported yield considers both ACMG variant classification and whether the genotype actually results in disease. Results: We report a diagnostic yield of at least 23% for our complete diagnostic cohort. The total diagnostic yield based solely on CNVs was 2.4%. The overall contribution of CNV analysis, defined as the proportion of positive genetic tests requiring CNV analysis, was 10.5% and varied among different disease subcategories, with the highest impact seen in congenital anomalies of the kidney and urinary tract and chronic kidney disease at a young age. We highlight the efficiency of exome-based CNV calling, which reduces the need for additional diagnostic tests. Furthermore, a complex structural variant, likely a COL4A4 founder variant, was identified. Additional findings unrelated to kidney diseases were reported in a small percentage of cases. This study also offers a comprehensive overview of our expert centre's diagnostic results over the past eight years covering both SNVs and CNVs. Conclusion: In summary, this study demonstrates the substantial diagnostic value of CNV analysis, providing insights into its contribution to the diagnostic yield and advocating for its routine inclusion in genetic testing of kidney disease patients.

Authors

Institutions

Publication Details

Journal
Journal of the American Society of Nephrology
Published
2024-10-01
DOI
https://doi.org/10.1681/asn.20249dxdes1d
Primary Topic
Genomics and Rare Diseases
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Importance of Copy Number Variant Analysis in Patients with Monogenic Kidney Diseases: Insights from 8 Years of Experience in an Expert Centre's Genome Diagnostic Laboratory

Laura R. Claus, Martin Elferink, Robert F. Ernst, Hanneke W. M. van Deutekom et al.
Journal of the American Society of Nephrology
Genomics and Rare Diseases
article

Importance of Copy Number Variant Analysis in Patients with Monogenic Kidney Diseases: Insights from 8 Years of Experience in an Expert Centre's Genome Diagnostic Laboratory

Laura R. Claus, Martin Elferink, Robert F. Ernst, Hanneke W. M. van Deutekom, Albertien M. van Eerde, Bert van der Zwaag
article en

Abstract

Background: Genetic testing can reveal monogenic causes of kidney diseases, offering diagnostic, therapeutic, and prognostic benefits. While single nucleotide variants (SNVs) and copy number variants (CNVs) can result in kidney disease, CNV analysis is not always included in genetic testing. With read depth-based tools for CNV detection (e.g. ExomeDepth) emerging, massively parallel sequencing can detect both SNVs and CNVs. This makes CNV detection more efficient as it does not require a separate test (e.g. SNP-array, MLPA). Methods: We investigated the diagnostic value of CNV analysis in 2,432 kidney disease patients genetically tested at the University Medical Centre Utrecht between 2014 and May 2022. We combined previous diagnostic testing results, encompassing SNVs and CNVs, with newly acquired results based on retrospective CNV analysis. The reported yield considers both ACMG variant classification and whether the genotype actually results in disease. Results: We report a diagnostic yield of at least 23% for our complete diagnostic cohort. The total diagnostic yield based solely on CNVs was 2.4%. The overall contribution of CNV analysis, defined as the proportion of positive genetic tests requiring CNV analysis, was 10.5% and varied among different disease subcategories, with the highest impact seen in congenital anomalies of the kidney and urinary tract and chronic kidney disease at a young age. We highlight the efficiency of exome-based CNV calling, which reduces the need for additional diagnostic tests. Furthermore, a complex structural variant, likely a COL4A4 founder variant, was identified. Additional findings unrelated to kidney diseases were reported in a small percentage of cases. This study also offers a comprehensive overview of our expert centre's diagnostic results over the past eight years covering both SNVs and CNVs. Conclusion: In summary, this study demonstrates the substantial diagnostic value of CNV analysis, providing insights into its contribution to the diagnostic yield and advocating for its routine inclusion in genetic testing of kidney disease patients.

Journal of the American Society of NephrologyVol. 35(10S)
Utrecht University (NL), University Medical Center Utrecht (NL), Netherlands Federation of University Medical Centres (NL)
Openalex Percentile: Top 78%
Genomics and Rare Diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.